Inhibitor Therapeutics Inc
inhibitortx.comWhat Do They Do?
Develops an itraconazole-based treatment for patients with basal cell carcinoma nevus syndrome, also known as Gorlin Syndrome.
10-K for FY2025, filed Mar 26, 2026
Who Are Their Customers?
Mayne Pharma provided royalty advances under the BCCNS supply and license agreement; the company says its business model is oriented toward potential licensing, partnerships or divestment of its lead program.
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 14, 2026
−$613.9KView ↗
- ▼ −7% (Loss)
- vs −$659.9K in Q2 FY2025
Narrower indication focus
The older report described plans to develop itraconazole for BCCNS, other cancers and non-cancerous disorders; the latest report centers the program on BCCNS.
10-K for FY2022, filed Mar 31, 2023 10-K for FY2025, filed Mar 26, 2026The new Board and management of INTI intend to continue the development of itraconazole for BCCNS, and other cancers and non-cancerous…View ↗
We are a pharmaceutical development company focused on the development and potential commercialization of therapeutics based on already…View ↗
Loading...
